Coll Plant Biotechnologies LTD CLGN
We take great care to ensure that the data presented and summarized in this overview for CollPlant Biotechnologies Ltd is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CLGN
View all-
Pinnacle Associates LTD530KShares$2.76 Million0.05% of portfolio
-
Investment Management Of Virginia LLC464KShares$2.41 Million0.63% of portfolio
-
Villere St Denis J & CO LLC367KShares$1.91 Million0.17% of portfolio
-
Roumell Asset Management, LLC Chevy Chase, MD315KShares$1.64 Million3.45% of portfolio
-
Brown Advisory Inc120KShares$621,5870.0% of portfolio
-
Benjamin F. Edwards & Company, Inc. St. Louis, MO50.5KShares$262,3400.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il13.2KShares$68,6030.0% of portfolio
-
Bank Of America Corp Charlotte, NC7.3KShares$37,9600.0% of portfolio
-
Ubs Group Ag4.78KShares$24,8560.0% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA3.6KShares$18,7200.0% of portfolio
Latest Institutional Activity in CLGN
Top Purchases
Top Sells
About CLGN
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Insider Transactions at CLGN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|